Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Transcript
How does implementing tools for increasing biosimilar use differ between smaller and larger practices?
So, at a smaller practice site where maybe you're operating only in 1 state or maybe you just have a few commercial payers, or even if a majority of your payer mix is government payers, you can probably adopt biosimilars in a full fledge swoop. So, all at once vs our approach, which has been a phased approach of initiating new patients on biosimilars and then choosing a biosimilar at prior authorization renewal. So, if you're in a smaller health system, and you're able to pick a preferred product—because, again, maybe your payer landscape is more standardized—then you can have one set implementation date, have reduced inventory burden, and just improve workflows going forward.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More